Skip to main content
Premium Trial:

Request an Annual Quote

HTG Licenses Merck's Breast Cancer Biomarker Patent Portfolio

NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics today announced it has licensed Merck's breast cancer biomarker patent portfolio.

The license allows HTG to develop, manufacture, and commercialize tests based on the portfolio, which is co-owned by the Netherlands Cancer Institute. Financial and other terms of the deal were not disclosed.

HTG CEO T.J. Johnson said that the firm intends to pursue approval from the US Food and Drug Administration for tests that provide "compelling medical value" and to make them available to local laboratories. "This patent portfolio license from Merck gives HTG access to key intellectual property to bring valuable breast cancer tests to market," he said in a statement.

Based in Tucson, Ariz., HTG announced in June a partnership with the John Wayne Cancer Institute to commercialize melanoma assays. Earlier in the year it inked a companion diagnostic deal with Sanofi US.

The Scan

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.

Adenine Base Editor Targets SCID Mutation in New Study

Researchers from the University of California, Los Angeles, report in Cell that adenine base editing was able to produce functional T lymphocytes in a model of severe combined immune deficiency.

Researchers Find Gene Affecting Alkaline Sensitivity in Plants

Researchers from the Chinese Academy of Science have found a locus affecting alkaline-salinity sensitivity, which could aid in efforts to improve crop productivity, as they report in Science.

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.